Related Experiment Video
Updated: Jul 4, 2026
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
Published on: January 3, 2025
Exploiting endogenous anti-apoptotic proteins for novel therapeutic strategies in cerebral ischemia
Abdelhaq Rami1, Ingo Bechmann, Jörg H Stehle
1Dr. Senckenbergische Anatomie, Institute of Cellular and Molecular Anatomy (Anatomie III), Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, D-60590 Frankfurt/Main, Germany. Rami@em.uni-frankfurt.de
Abstract:
The acute neuronal degeneration in the ischemic core upon stroke is followed by a second wave of cell demise in the ischemic penumbra and neuroanatomically connected sites. This temporally delayed deleterious event of programmed cell death ('secondary degeneration') often exceeds the initial damage of stroke and, thus, contributes pivotally to significant losses in neurological functions. In fact, it is the injured neurons in these regions around the ischemic core zone that neuropharmacological prevention is targeting to preserve. Clinical and pre-clinical studies have focussed on neuroprotective interventions with caspase inhibitors, but it remains ambiguous whether diminishing or even silencing these aspartate-specific cysteine proteases are in sum beneficial for the clinical outcome. It is often ignored that caspase inhibitors are able to antagonize calpain and cathepsins, thereby protecting the cytoskeleton from damage. Moreover, there is a point of no return, beyond which interfering with caspases cannot rescue the cell, but spoil the obligate and necessary suicide program such that the cellular environment suffers from by-products of necrosis and secondary inflammation. Here we discuss novel alternative strategies to abrogate the death cascade at the level of the genomic response (transcription factors, NF-kappaB, CREB, ICER, HIF), of mitochondrial effectors (cytochrome c, Bcl-2, Smac/DIABLO, HtrA2), and of inhibitor of apoptosis proteins (IAPs). IAPs are the only known endogenous proteins that inhibit specifically and with high affinity the activity of both initiator and effector caspases. Based on compelling biochemical evidence, we argue that patronizing the neuronal endogenous anti-apoptotic machinery could be superior to the pharmacological inhibition of caspases at various levels, with regard to specificity, side effects, and the 'therapeutic window of opportunity'.
Insights
Secondary degeneration after stroke causes significant neurological deficits. Targeting the endogenous anti-apoptotic machinery offers a superior neuroprotective strategy compared to caspase inhibitors, improving therapeutic outcomes.
Area of Science:
- Neuroscience
- Cell Biology
- Pharmacology
Background:
- Stroke induces acute neuronal death in the ischemic core, followed by delayed programmed cell death (secondary degeneration) in surrounding areas, leading to functional loss.
- Neuroprotective strategies aim to prevent this secondary degeneration, with clinical and preclinical studies focusing on caspase inhibitors.
- The efficacy and side effects of caspase inhibitors are debated, as they can affect other cellular processes and may interfere with necessary cell death pathways.
Purpose of the Study:
- To explore alternative neuroprotective strategies beyond caspase inhibition for stroke treatment.
- To discuss novel approaches targeting the genomic response, mitochondrial effectors, and inhibitor of apoptosis proteins (IAPs).
- To argue for the superiority of enhancing endogenous anti-apoptotic mechanisms over direct caspase inhibition.
Main Methods:
- Review of existing clinical and preclinical data on neuroprotection after stroke.
- Discussion of molecular mechanisms involved in programmed cell death cascades.
- Analysis of the roles of transcription factors, mitochondrial proteins, and IAPs in neuronal survival.
Main Results:
- Caspase inhibitors have off-target effects, inhibiting calpains and cathepsins, and can disrupt essential cell death programs, leading to necrosis and inflammation.
- Targeting the genomic response (e.g., NF-kappaB, CREB, HIF), mitochondrial pathways (e.g., Bcl-2, Smac/DIABLO), and IAPs offers alternative therapeutic avenues.
- IAPs are endogenous inhibitors of both initiator and effector caspases.
Conclusions:
- Enhancing the brain's endogenous anti-apoptotic machinery presents a potentially more effective neuroprotective strategy than pharmacological caspase inhibition.
- This approach may offer improved specificity, reduced side effects, and a wider therapeutic window for treating stroke-induced neuronal damage.
- Further research into modulating endogenous protective pathways is warranted for stroke therapeutics.
